Metagenomi (NASDAQ:MGX) Stock, Quote.Headers.trade-ideas

Metagenomi

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).

Insights From Analysts

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BLMN

CCOI

CRWD

GNSS

PANW

PGNY

SNOW

Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday

Moderna_COVID-19_vaccine_(2021)_G

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

MRNA

Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance reaffirms $4 billion sales target for 2024.

Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars

Metagenomi Inc

MGX Minerals Inc

This is subject to the completion of the Reverse Stock Split.

GSAT

Globalstar Intends To Voluntarily Delist From NYSE American And Transfer To Nasdaq

The data will be presented in a poster session (abstract #206) at the American Society of Clinical Oncology 2025 Gastrointestinal Cancer Symposium (ASCO GI) being held January 23-25, 2025, in San Francisco.
"We are very encouraged by the initial Phase 2 proof-of-concept data for the combination of vilastobart and atezolizumab in heavily pre-treated patients with MSS colorectal cancer, including partial responses accompanied by marked decreases in tumor biomarkers and improvement in clinical symptoms," said Katarina Luptakova, M.D., chief medical officer of Xilio.

Xilio Reports Initial Data From Ongoing Phase 2 Clinical Trial Evaluating Vilastobart In Combination With Atezolizumab; 27% Preliminary Response Rate Observed In Heavily Pre-Treated Microsatellite Stable Colorectal Cancer Patients Without Liver Metastases

The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is subject to market and other conditions and the completion of the SEC's review process.

IPOs

Voyager Technologies Submits Confidential Registration Statement For Proposed IPO

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 19.56% on an annualized basis producing an average annual return of 28.09%. Currently, Intuitive Surgical has a market capitalization of $215.49 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 20 years ago, it would be worth $13,941.23 today based on a price of $605.00 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737499516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

Here's How Much $100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth Today

East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) has outperformed the market over the past 5 years by 3.68% on an annualized basis producing an average annual return of 16.95%. Currently, East West Bancorp has a market capitalization of $14.38 billion. 
Buying $1000 In EWBC: If an investor had bought $1000 of EWBC stock 5 years ago, it would be worth $2,106.64 today based on a price of $103.71 for EWBC at the time of writing.
<h3>East West Bancorp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737498617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EWBC

Here's How Much You Would Have Made Owning East West Bancorp Stock In The Last 5 Years

Contracts

GOOG

IAC Enters Further Amendment To Its Services Agreement With Google; Expiration Date Of Agreement Is Now March 31, 2026, With An Automatic Renewal For An Additional One-year Period - Filing

Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares are trading higher in Tuesday&#8217;s after-hours session after Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported better-than-expected <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">financial results for the fourth quarter</a>.
What Happened With Netflix: Netflix reported fourth-quarter revenue of $10.25 billion, beating analysts estimates of $10.11 billion. The streaming giant reported quarterly earnings of $4.27 per share, beating analyst estimates of $4.19 per share.
Shares appear to be soaring in response to the company&#8217;s strong subscriber growth. Netflix said it added 18.91 million paid subscribers in the quarter, bringing its total subscriber count up to 301.63 million.
Netflix noted that its advertising plan continues to be quite popular, generating over 55% of sign-ups in the quarter. The company&#8217;s ads plan grew nearly 30% on a quarter-over-quarter basis.
&#8220;We're on track to reach sufficient scale for ads members in all of our ads countries in 2025. A top priority in 2025 is to improve our offering for advertisers so that we can substantially grow our advertising revenue,&#8221; the company said. 
NFLX Earnings: <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">Netflix Q4 Earnings: Record Subscribers, NFL, &#8216;Squid Game&#8217; Push Past &#8216;Highest Expectations&#8217;</a>
Why It Matters For ROKU: Roku is well-positioned to benefit from strong advertising trends from Netflix and other streaming companies.
Roku creates revenue opportunities with streaming companies through partnerships and advertising. The company operates an advertising distribution platform, allowing it to capitalize on the growth of streaming. Netflix was reportedly <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/06/27622300/3-reasons-why-this-analyst-thinks-a-netflix-roku-deal-may-not-materialize" target="_blank" rel="noreferrer noopener">considering a takeover of Roku</a> a couple of years ago, but a deal never materialized.
Roku is due to report its <a href="https://www.benzinga.com/calendars/earnings">fourth-quarter financial results</a> in early February, although a date has not yet been confirmed by the company. Analysts expect Roku to report a loss of 41 cents per share and revenue of $1.15 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
ROKU Price Action: <a href="http://benzinga.com/quote/roku">Roku shares</a> were up 3.71% in after-hours, trading at $82.70 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Entertainment

After-Hours Center

Media

NFLX

ROKU

Roku Stock Is Rising After-Hours Tuesday: Here's Why

As of January 17, 2025, a total of approximately 13.24 million shares remained available for repurchase under the existing repurchase authorization, resulting in an increase of 6.75 million shares of common stock available for repurchase.

Buybacks

HOMB

Home BancShares Increases Share Repurchase Program And Renew Authorization To 20M Shares

Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively.
Results from prospective molecular residual disease (MRD) study show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients.
In addition to the data shared at ASCO GI, Oncodetect achieved its primary endpoint in the Beta-CORRECT study.&nbsp;
&nbsp;
&nbsp;

EXAS

Exact Sciences Says Oncodetect Test Achieved Primary Endpoint In Second Clinical Validation Study, Extending Prognostic Value Into Stages II And IV Colon Cancer And Rectal Cancer

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 6.58% on an annualized basis producing an average annual return of 18.61%. Currently, Centene has a market capitalization of $32.14 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 15 years ago, it would be worth $13,092.03 today based on a price of $63.66 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737497710_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Centene 15 Years Ago Would Be Worth This Much Today

Exact Sciences Plans To Present 11 Abstracts At ASCO GI Meeting In San Francisco

Efficacy was assessed in 10 of the 13 patients who received at least one dose of ozekibart, based on RECIST v1.1 criteria. Results demonstrated one complete response (CR), three partial responses (PR), and six cases of stable disease (SD). Durable disease control lasting ≥180 days was observed in 46.2% of patients, with a median progression-free survival (PFS) of 7.85 months.&nbsp;
Encouraged by these preliminary results, Inhibrx has initiated a new expansion cohort to validate these findings in a more uniform patient population. The cohort is expected to enroll up to 50 patients, each with two to three prior lines of systemic therapy, and data are anticipated in Q3 2025.

INBX

Inhibrx Reports Preliminary Efficacy And Safety Data From Phase 1 Trial Of Ozekibart (INBRX-109) For Treatment Of Colorectal Cancer; Initiates New Expansion Cohort To Validate Findings

ORLA

Orla Mining Says Shareholders Approved Acquisition Of Musselwhite Mine From Newmont

Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares closed Tuesday down more than 11% following U.S. President Donald Trump&#8217;s inauguration. Here&#8217;s what <a href="https://www.benzinga.com/general/social-media/25/01/43091739/djt-stock-drops-3-in-tuesday-premarket-a-day-after-inauguration-key-details-about-trumps-media-company">you need to know</a>.
What To Know: Shares of Trump Media, the parent company of social media platform&nbsp;Truth Social,&nbsp;took a beating on Tuesday in the wake of Trump&#8217;s inauguration. The stock has moved up and down in recent months alongside Trump's&nbsp;chances of reelection. 
Despite Tuesday&#8217;s sharp decline, Trump Media shares are still up close to 14% over the past three months, buoyed by Trump&#8217;s election win in November. Trump owns more than a 50% stake in Trump Media, or roughly 114.5 million shares.
It&#8217;s possible that some of the profit-taking in Trump Media shares on Tuesday could be the result of money flowing into Trump&#8217;s recently-launched meme coin Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>), which was up approximately 18% over 24 hours at last check.
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43105356/meme-coin-supercycle-dogecoin-trump-bonk-futures-etf-applications-filed">Meme Coin Supercycle? Dogecoin, Trump, Bonk Futures ETF Applications Filed</a>
Trump Media is due to report financial results for the fourth quarter in about two weeks. In the third quarter, Trump Media reported a net loss of $19.2 million and revenue of just $1.01 million, which was down 6% year-over-year. 
Trump Media management acknowledged last quarter that the price action in Trump Media shares may be detached from the company's fundamentals because of its ties to Trump.
"TMTG's success depends in part on the popularity of our brand and the reputation and popularity of President Donald J. Trump. The value of TMTG's brand may diminish if the popularity of President Donald J. Trump were to suffer," the company said in its third-quarter earnings release.
DJT Price Action: <a href="http://benzinga.com/quote/djt">Trump Media shares</a> closed Tuesday down 11.09% at $35.59. The stock was down another 0.45% in after-hours trading at the time of publication Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43109461/gold-miners-defense-stocks-shine-while-solar-tanks-following-trumps-day-1-actions">Trump&#8217;s First Day Sends Gold Miners, Defense Stocks Soaring, Solar Sliding</a></li>
</ul>
Photo: Shutterstock.

Politics

$TRUMP

What Happened To Trump Media & Technology Group Stock Tuesday?

New data will include initial results from the 20 mg/kg loading dose followed by 10 mg/kg Q3W in combination with pembrolizumab.
 &nbsp;

ADAG

Adagene To Share Updated Clinical Data From ADG126 In Microsatellite Stable Colorectal Cancer At ASCO Gastrointestinal Cancers Symposium On January 25, 2025.

SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.51 by 11.76 percent. This is a 39.02 percent increase over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $46.81 million which beat the analyst consensus estimate of $44.37 million by 5.51 percent. This is a 19.74 percent increase over sales of $39.10 million the same period last year.

Earnings Beats

SMBK

SmartFinancial Q4 2024 Adj EPS $0.57 Beats $0.51 Estimate, Sales $46.81M Beat $44.37M Estimate

Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.78 by 6.74 percent. This is a 13.1 percent increase over earnings of $1.68 per share from the same period last year. The company reported quarterly sales of $475.33 million which beat the analyst consensus estimate of $471.49 million by 0.82 percent. This is a 19.93 percent increase over sales of $396.34 million the same period last year.

PNFP

Pinnacle Finl Partners Q4 2024 Adj EPS $1.90 Beats $1.78 Estimate, Sales $475.33M Beat $471.49M Estimate

PDCO

Patterson Companies Reports Expiration Of "Go-Shop" Period; Patient Square Transaction Is Expected To Close In April

Analysts' ratings for N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.2, a high estimate of $16.50, and a low estimate of $11.00. A 4.31% drop is evident in the current average compared to the previous average price target of $14.84. 
<img src="https://www.benzinga.com/files/images/story/2025/1737496879_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of N-able among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$11.00</td>
<td>$11.20</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.50</td>
<td>$16.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to N-able. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of N-able compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of N-able's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into N-able's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NABL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on N-able analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About N-able</h2>
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. it also has a presence in the United Kingdom and all other International regions.
<h3>N-able: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: N-able's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 8.25%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: N-able's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.24% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): N-able's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): N-able's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.9% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: N-able's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NABL

What Analysts Are Saying About N-able Stock

12 analysts have shared their evaluations of Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $52.33, a high estimate of $61.00, and a low estimate of $44.00. This current average represents a 7.38% decrease from the previous average price target of $56.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1737496863_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Schlumberger. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$44.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$61.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$59.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Schlumberger. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Schlumberger compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Schlumberger's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Schlumberger's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Schlumberger analyst ratings.</a>
<h2>All You Need to Know About Schlumberger</h2>
SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts well over $1 billion in digital-related revenue.
<h3>Understanding the Numbers: Schlumberger's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Schlumberger displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 10.22%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Schlumberger's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.95%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.39%, the company showcases effective utilization of assets.
Debt Management: Schlumberger's debt-to-equity ratio is below the industry average. With a ratio of 0.6, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Schlumberger Stock: Analyst Perspectives (12 Ratings)

There's been something of a sea change in the economic outlook for 2025, in the aftermath of last month's election. The prospect of a second Trump ...

Jefferies Predicts Up to ~1000% Surge for These 2 'Strong Buy' Stocks

The company states: "Metagenomi (MGX) presented updated preclinical NHP data for its hemophilia A program in an oral presentation (link here) at th...

Metagenomi presents updated preclinical data in Hemophilia A at ASH

Metagenomi (MGX) presented updated preclinical NHP data for its hemophilia A program in an oral presentation at the American Society of Hematology,...

Metagenomi presents updated preclinical NHP data at ASH meeting

H.C. Wainwright raised the firm's price target on Metagenomi (MGX) to $14 from $7 and keeps a Buy rating on the shares after the company reported 1...

Metagenomi price target raised to $14 from $7 at H.C. Wainwright

In a report released on December 10, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report), with...

Upgraded Buy Rating for Metagenomi, Inc. Driven by Promising Hemophilia A Program and Strong Financial Position

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report), with a price target...

Metagenomi's Gene Editing Breakthroughs and FVIII Advancements Propel Buy Rating

Metagenomi (MGX) announced that Eric Bjerkholt, CFO of Mirum Pharmaceuticals (MIRM), will join Metagenomi's Board of Directors, serving on Metageno...

Metagenomi appoints Eric Bjerkholt to board of directors

"Our vision at Metagenomi (MGX) is to create curative genetic medicines for patients by harnessing the power of our metagenomics platform," said Br...

Metagenomi outlines anticipated 2025 milestones

Metagenomi, Inc. ( ($MGX) ) has shared an announcement. On January 13, 2025, Metagenomi, Inc. announced the expansion of its board of directors by ...

Metagenomi Expands Leadership and Showcases Innovations

Analyst Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report) and keeping the price target at $25.00. Yana...

Promising Outlook for Metagenomi, Inc.: Strategic Collaborations and Technological Advancements Drive Buy Rating

GPCR

MIRM

Legal

Press Releases

DEADLINE ALERT for BMBL, MGX, POWW, and FNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

MGX DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGX

DEADLINE ALERT for BMBL, MGX, POWW, FNA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Comments

Metagenomi

Metagenomi (MGX) Forecast

Metagenomi (NASDAQ:MGX) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga